BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34228163)

  • 1. Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.
    Zhang W; Li Z; Liu M; Mu Y; He J; Chen P; Liu D; Chen K; Che B; Xu S; Zhang H; Tang K
    World J Urol; 2021 Dec; 39(12):4413-4419. PubMed ID: 34228163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH; Kim Y; Park YW; Lee DG
    J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population.
    Park JS; Koo KC; Kim HK; Chung BH; Lee KS
    Medicine (Baltimore); 2019 Oct; 98(42):e17635. PubMed ID: 31626149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population.
    Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK
    Asian Pac J Cancer Prev; 2010; 11(2):365-70. PubMed ID: 20843117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
    Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
    BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms.
    Zhao S; Chen C; Chen Z; Xia M; Tang J; Shao S; Yan Y
    Urol J; 2016 Jun; 13(3):2717-26. PubMed ID: 27351328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
    Zhao S; Tang J; Shao S; Yan Y
    Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The independent association of non-alcoholic fatty liver disease with lower urinary tract symptoms/benign prostatic hyperplasia and erectile function scores.
    Eren H; Horsanali MO
    BJU Int; 2019 Aug; 124(2):329-335. PubMed ID: 30900792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
    Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
    BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population.
    Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK
    Asian Pac J Cancer Prev; 2010; 11(4):1067-72. PubMed ID: 21133626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
    Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
    BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between anogenital distance and benign prostatic hyperplasia related lower urinary tract symptoms in Chinese aging men.
    Lu Y; Fan S; Song Y; Liu K; Zhou K; Kang J; Wang S; Yang Y; Liu X
    World J Urol; 2021 Jul; 39(7):2645-2653. PubMed ID: 33141318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
    Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
    BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
    Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
    Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population.
    Qadri Q; Sameer AS; Shah ZA; Hamid A; Alam S; Manzoor S; Siddiqi MA
    Genet Mol Res; 2011 Dec; 10(4):3038-45. PubMed ID: 22180037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Viktrup L; Hayes RP; Wang P; Shen W
    BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Effects of Oral Supplementation of Gamma-Cyclodextrin Curcumin Complex in Male Patients with Moderate-To-Severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms.
    Crocerossa F; Cantiello F; Bagalá L; Sicoli F; Carbonara U; Manfredi C; Falagario U; Veccia A; Pandolfo SD; Napolitano L; Ferro M; Di Dio M; Mondaini N; Damiano R
    Urol Int; 2023; 107(10-12):924-934. PubMed ID: 37939691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.